We studied the effects of multi-and single-target liposomal drugs on human gastric cancer cell AGS both in vitro and in vivo. The cytotoxic effect of dihydrotanshinone I was significantly enhanced by treatment with octreotide-polyethylene glycol(PEG)-liposome, Arg-GlyAsp(RGD)-PEG-liposome, and RGD/octreotide-PEGliposome encapsulated with 0.5 g/ml of dihydrotanshinone I to AGS cell for 24 h, compared to control. Furthermore, the AGS cell survival rate for multi-target versus single target liposomal drugs was significantly suppressed. Microsocpic examination revealed that significant cell death occurred in the multi-and singletarget liposomal encapsulated drug groups. Significant suppression of tumor growth in AGS cell xenograft nude mice given octreotide-PEG-liposome, RGD/octreotide-PEG-liposome encapsulated drug, versus those given a free drug was noted after 13 d of experimentation with the multi-targeted liposome: up to 60.75% and 41.2% reduction of tumor volume as compared to dimethylsulfoxide (DMSO) control and the free drug groups respectively. The treated animals showed no gross signs of toxicity. The results have potential clinical application.
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Key words: liposome; octreotide; Arg-Gly-Asp (RGD); xenograft; gastric cancer Dihydrotanshinone I is a lipid-soluable component obtained from Danshen, the root of a Chinese herb, Salvia miltiorrhiza, which has been suggested to exert various biological functions, including anti-inflammation, 1) anti-platelet, 2) liver protection, 3) and anti-tumor effects. [4] [5] [6] Recent reports have suggested that dihydrotanshinone I inhibited topoisomerase I derived from the calf thymus, 7) and induction of growth arrest at the S phase and apoptosis of a multidrug resistance erythroleukemia cell line, K562/ADR. 8) These findings indicate the potential anti-tumor effect of dihydrotanshinone I, but at relatively high dosage (10 mg/ml). Finding strategies to enhance dihydrotanshinone I and other potential anti-tumor agents' effects toward cancer cells without damaging normal cells is an important issue. One approach is through liposome-carriage of drugs.
Liposome is a single or multi-lamellar vesicle (MLV) with a self-closing feature.
9) It has both a hydrophilic head region and a hydrophobic carbon chain for the carriage of various drugs.
10) It is mainly composed of natural phospholipid, which makes it highly bio-compatible and bio-degradable. Conventional liposome has been used in the carriage of drugs in cancer treatment. 11, 12) Due to its low specificity and stability, clinical usage is limited. In recent years, liposome has been modified either with polyethylene glycol (PEG) to prolong its stability in circulation, 13) or with targeting molecules to interact with specific cells. 14, 15) The development of covalent binding of targeting molecules with PEG on liposome makes improved stability and specificity possible at the same time. [16] [17] [18] Gastric cancer is the second leading cause of cancerassociated deaths worldwide. 19, 20) Importantly, its incidence is 6-8 times greater in Asian and Eastern European countries. 19, 20) Surgical treatment is effective * Contributed equally y To whom correspondence should be addressed. Tel: +886-2-27361661 ext.3010; Fax: +886-2-27393422; E-mail: sylin@tmu.edu.tw Abbreviations: DMSO, dimethylsulfoxide; DSPE-PEG, distearoylphosphatidyl-ethanolamine-N-poly(ethyleneglycol); FCS, fetal calf serum; MLV, multi-lamellar vesicle; MTT, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-2H-tetrazolium bromide; PEG, polyethylene glycol; RGD, Arg-Gly-Asp; SANPAH, succinimidyl-6-(4 0 -azido-2 0 -nitrophenylamino) hexanoate for patients with early-stage disease. However, for those patients with regional or distant metastasis at the time of diagnosis, only 20-40% respond to chemotherapy. 21) Therefore, new modalities are necessary for the treatment of patients with advanced gastric cancer.
Octreotide is a somatostatin analog composed of eight amino acids. 22) As compared to somatostatin, it has higher efficacy and a longer half-life in the circulatory system. 22, 23) The gastrointestinal tract is a major source and target of somatostatin, and the receptor for somatostatin has been detected in gastric carcinoma. 24) It has been found that somatostatin subtype 2 and 5 receptors are expressed in human gastric cancer cell AGS. 25) The RGD sequence in the ligand is specifically recognized by integrin receptors. The v3 integrin is highly expressed in vessels surrounding the tumor. 26) Suppression of the expression of v3 integrin has been associated with apoptosis of endothelial cells, which inhibited tumor growth. 27, 28) The purpose of this study, using RGD or/and octreotide in preparing single and multi-target covalent PEG binding liposome encapsulated drugs, was to compare their cytotoxic effects with free drugs on AGS cells both in vitro and in vivo.
Materials and Methods
Distearoylphosphatidyl-ethanolamine-N-poly(ethyleneglycol) (DSPE-PEG) conjugation, and analysis and preparation of liposome. Liposome compositions DSPE-PEG-Oct and DSPE-PEG-RGD were kindly provided by Professor Shui-Tein Chen, Academia Sinica, Taiwan. The method of DSPE-PEG-Oct and DSPE-PEG-RGD has been described elsewhere in detail. 29) The lipid mixtures and hydrophobic dihydrotanshinone I were dissolved in chloroform. The organic solvents were then removed with a rotary evaporator under reduced pressure. A thin film of lipid was observed after the solvents were removed. Normal saline was then added to hydrate the thin lipid film. Hydration was followed by sonication in a water bath for at least 10-15 min to form an MLV suspension. The MLV liposomal suspension was then moved into a probe sonicator for 10 min at 50 C to form a small unilamellar vesicle suspension.
Cell line and cell culture. AGS, a cell line obtained from human gastric cancer, (American Type Culture Collection, Manassas, VA) was maintained in 1:1 DME/ F-12 (v/v) supplemented with 10% fetal calf serum (FCS), penicillin (100 U/ml), streptomycin (100 mg/ ml), and 0.3 mg/ml glutamine in a humidified incubator (37 C, 5% CO 2 ). Dihydrotanshinone I (Xi'an Honson Biotechnology Co., Xi'an, China) was added at the indicated doses in 0.1% dimethylsulfoxide (DMSO). For control specimens, the same volume of DMSO was added to a final concentration of 0.1% (v/v) without dihydrotanshinone I.
Determination of cell viability. Cell viability was determined by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-2H-tetrazolium bromide (MTT) assay, as described previously. 30) Briefly, cells were seeded in a 24-well plate at a density of 1 Â 10 5 cells/well and allowed to adhere overnight. After removal of the medium, 900 ml of fresh medium per well, containing 10 mmol/l Hepes (pH 7.4), was added. Then 50 ml of MTT was added to the wells and the plate was incubated for 2 h at 37 C in the dark. The medium was removed, and 1000 ml of DMSO and 125 ml of Sorensens's glycine buffer was added to the wells. Absorbance was measured using an ELISA plate reader at 570 nm.
Experimental animals. Male, 4-5 week old, BALB/ cAnN.Cg-Foxn1 nu /CrlNarl mice (National Laboratory Animal Center, Taipei, Taiwan) were housed in plastic cages (5 mice/cage), with wire tops and wood-chip bedding and in a control room under a 12/12 (light/ dark) cycle at a ventilation rate of 12 l/h, a humidity of 60 AE 5%, and a temperature of 23 AE 2 C. Food and water were available ad lib. All experimental animal treatment followed the guidelines set up by the Institutional Animal Care and Use Committee of Taipei Medical University. 2 xL, where W = width and L = length of the tumor, as previously described. 31) Mice were weighed every day and sacrificed at day 13, and their general health was monitored during the assay. Immunohistochemistry study. As described previously, 32) paraffin-embedded blocks were sectioned at 5-7 mm thickness. After microwave pretreatment in citrate buffer (pH 6.0) for antigen retrieval, slides were immersed in 0.3% hydrogen peroxide for 20 min to block endogenous peroxidase activity. After intensive washing with PBS, the slides were incubated overnight at 4 C with anti-Ki67 or anti-CD34 (Dako, Carpinteria, CA) antibody at a dilution of 1:100. After incubation with a biotinylated secondary antibody (1:200), the slides were incubated with peroxidase-conjugated streptavidin (Dako LSAB+kit; Dako). Reaction products were visualized by immersing the slides in diaminobenzidine tetrachloride, and finally counterstained with hematoxylin.
Statistics. Results were expressed as mean AE S.E. for each study. Data were subjected to one-way analysis of variance (ANOVA), followed by Student's t-test. A P value of 0.05 or less was considered statistically significant.
Results
First we used a spectrophotometer to obtain standard lines for RGD-SANPAH (succinimidyl-6-(4 0 -azido-2 0 -nitrophenylamino) hexanoate) and octreotide-SANPAH. The concentration of 260 ml of RGD-SANPAH was 9 mM, 0.0116 mM at a volume of 200 ml. The absorption intensity outside the dialysis membrane was 0.0115. Calculation was by the standard line formula for RGD-SANPAH: y ¼ 2:918x þ 0:006, where x is 0.0017 mM. Therefore, the graft density of RGD-SANPAH, was 1-0.0017 mM/0.0116 mM equal to 85.34%, which represents the conjugation percentage of DSPE-PEG-RGD. The concentration of 180 ml of octreotide-SANPAH was 5 mM, 0.0045 mM at a volume of 200 ml. The absorption intensity outside the dialysis membrane was 0.0262. Calculation was by the standard line formula for octreotide-SANPAH: y ¼ 19:78x À 0:018, where x is 0.0014 mM. Therefore, the graft density of octreotide-SANPAH was 1-0.0014 mM/0.0045 mM equal to 69%, which represents the conjugation percentage of DSPE-PEG-octreotide.
MTT assay was performed to test the anti-proliferative effect of dihydrotanshinone I on AGS cells. As shown in Fig. 1 , treatment of AGS cells with 1 to 10 mg/ ml dihydrotanshinone I for 24 h dose-dependently suppressed AGS cell proliferation. Dihydrotanshinone I at conentrations 5 and 10 mg/ml significantly inhibited AGS cell proliferation, from 61.85% to 84.05% as compared to control respectively. There was no effect on AGS cell proliferation at a concentration of 0.5 mg/ ml of dihydrotanshinone I.
Liposomes with compositions of octreotide-PEG-liposome, RGD-PEG-liposome, and RGD/octreotide-PEGliposome at a concentration of 5 mM were used to encapsulate 0.5 mg/ml of dihydrotanshinone I. As shown in Fig. 2 , MTT assay, treatment with the dihydrotanshinone I free drug and empty liposome for 24 h had no effect on AGS viability as compared to the control, indicating that liposome at this concentration had no µg/ml % of control toxicity on AGS cells. However, treatment with octreotide-PEG-liposome, RGD-PEG-liposome, and RGD/ octreotide-PEG-liposome encapsulated with 0.5 mg/ml dihydrotanshinone I for 24 h significantly suppressed AGS cell growth as compared to the control, suggesting that liposome encapsulation enhanced the cytotoxic effect of dihydrotanshinone I on AGS cells. Furthermore, the AGS cell survival rates for octreotide-PEGliposome, RGD-PEG-liposome, and RGD/octreotide-PEG-liposome were 7.41%, 19.7% and 2.66% respectively after 24 h of treatment. The multi-target liposomal drug showed significant enhancement of cytotoxicity on AGS cells, as compared to the single-target liposomal drug.
A similar experimental design was conducted in Fig. 2 , but the cells were directly observed under a light microscope at 40Â and 200Â magnification. As shown in Fig. 3A , the low-power magnification, treatment with dihydrotanshinone I free drug and empty liposome for 24 h had no effect on AGS cell morphology as compared to the control, indicating that liposome under this concentration had no toxicity on AGS cells. However, We next examined whether administration of various liposome compositions of encapsulated dihydrotanshinone I would affect the growth of tumors derived from human gastric cancer cells in an in vivo setting. As shown in Fig. 4A , reductions in tumor volume in mice given octreotide-PEG-liposome, RGD-PEG-liposome, and RGD/octreotide-PEG-liposome versus those given free drug were detected after 7 d of treatment. This difference became progressively more conspicuous, the average tumor volume of octreotide-PEG-liposome and RGD/octreotide-PEG-liposome-treated mice differing significantly from the free drug group after 13 d of experimentation with the multi-targeted liposome, up to 60.75% and 41.2% reductions in tumor volume as compared to the control and free drug groups respectively. However, as shown in Fig. 4B , there was no significant change in body weight among the treatment groups.
A previous report explained that monoclonal antibody Ki67, which recognizes a human nucleus antigen that is present in proliferating cells but absent in resting cells, 33) can be used as a marker of the tumor proliferative fraction. CD34 is an endothelial antigen that has been used to determine microvasculature vessel density as a direct marker of the degree of angiogenesis. 34) To test the in vivo effects of octreotide and of RGD-based liposome on cell proliferation and angiogenesis respectively, an immunohistochemistry study was performed using AGS tumor xenograft. As shown in Fig. 5A , brown staining by anti-Ki67 antibody in octreotide-PEGliposome and RGD/octreotide-PEG-liposome decreased as compared to the control, suggesting inhibition of cell proliferation. Also shown in Fig. 5B , brown staining by anti-CD34 antibody in RGD-PEG-liposome and RGD/ octreotide-PEG-liposome decreased as compared to the control, suggesting inhibition of angiogenesis. These findings indicate that targeting of molecules on liposome can be specifically effective in vivo.
Discussion
In the present study, we found that RGD/octreotide covalent PEG binding liposome enhanced the anticancer effect of dihydrotanshinone I on AGS cells in cell culture and nude mice xenograft models. The treated nude mice showed no significant toxicity during the experiments. To our knowledge, this is the first demonstration that single or multi-target liposome inhibits the growth of gastric cancer cells both in vitro and in vivo.
Targeting of somatostatin receptor by octreotide has been found to provide cell selectivity with lower toxicity, 35) and to enhance antitumor action against gastic cancer cells. 25) Angiogenic vascular endothelial cells targeted by RGD-PEG-liposome has been found to enhance the treatment effect in a mouse experimental arthritis model by specific association with blood vessels at the site of inflammation. 36) Furthermore, RGD-modified sterically stabilized liposome has been found to enhance the antitumor effect of doxorubicin both in vitro and in vivo. 37) In Fig. 2 , MTT assay of AGS cells with various non-encapsulated or encapsulated liposomes, we found that PEG-liposome (empty) control showed no significant cytotoxicity. We also tested the cytotoxic effect of non-encapsulated liposome controls, such as octreotide-PEG-liposome, RGD-PEG-liposome, and RGD/octreotide-liposome. These showed no significant toxicity as compared with PEG-liposome (unpublished data). These findings are supported by previous reports that RGD or somatostatin-targeting liposome or carrier showed no apparent toxicity. 35, 37) Hence, we inferred that the in vitro anti-tumor effects of various liposomes of encapsulated TSDH is in part due to targeting mechanism. As Fig. 4B also shows, no significant difference in body weight change occurred between the target-liposome and control groups, suggesting no significant toxicity. One study found that the RGD-modified liposome loaded with doxorubicin caused no increase in doxorubicin accumulation in the liver, lung, kidney, or heart of mice as compared to non-targeting liposome. 38) Taken together, these findings suggest that a targeting mechanism is involved in the anti-tumor effect of various liposome of encapsulated TSDH in vivo. Our results indicate that multi-target RGD/octreotide-PEG-liposome further enhanced antitumor action as compared to single-target RGD-PEGliposome and octreotide-PEG-liposome. An immunohistochemistry study with anti-Ki67 and anti-CD34 indicated the specific involvement of target molecules in anti-proliferation and antiangiogensis effects on AGS tumor xenograft, suggesting that a multi-target liposome can have additive effects through different signaling mechansisms.
The molecular mechanism of dihydrotanshinone I anti-cancer effects remains elusive. It was found that dihydrotanshinone I reduced topoisomerase I activity 7) and induced apoptosis in leukemia cells. 8) Previous reports have suggested that topoisomerase I inhibitors, such as camptothecin, CPT-11, and SN-38, induce apoptosis in human cancer cells, 39, 40) involving stabilization of the topoisomerase I-DNA complex and generation of strand breaks and cell death. 41) In our study, treatment with single or multi-target covalent PEG binding liposome-encapsulated dihydrotanshinone I, but not liposome vehicle, significantly induced cell death as judged by microscopic examination of AGS cells, suggesting activation of apoptosis by dihydrotanshinone I.
In conclusion, RGD/octreotide-PEG-liposome enhanced the antitumor activity of encapsulated dihydrotanshinone I against gastric cancer cells without gross toxicity. The results from the present in vitro and in vivo studies suggest that multi-target liposomal drugs have potential applications in clinical usage.
